Clinical Trials by Drug Mechanism / Class

Browse recruiting clinical trials by therapeutic mechanism class. Mechanism hubs are useful when your oncologist mentioned a drug class by name (for example, "BCMA bispecific" or "PSMA radioligand") and you want to see all the recruiting options in that class side-by-side. For most patients, browsing by disease is the right starting point.

Data from ClinicalTrials.gov

Multiple Myeloma — Bispecific T-Cell Engagers

BCMA × CD3 Bispecifics

65 recruiting trials

Target: BCMA (B-cell maturation antigen). Three FDA-approved drugs: teclistamab (Tecvayli), elranatamab (Elrexfio), linvoseltamab (Lynozyfic). Most-validated MM bispecific class. Plus cevostamab (FcRH5, related class).
GPRC5D × CD3 Bispecifics

25 recruiting trials

Target: GPRC5D (orphan G-protein-coupled receptor). FDA-approved: talquetamab (Talvey). Plus JNJ-79635322 BCMA × GPRC5D dual-bispecific and SIM0500 trispecific. Alternative class for post-BCMA sequencing.

Coming Soon — Planned Mechanism Hubs

PSMA Radioligand Therapy

Hub coming soon

Target: PSMA. Radiopharmaceuticals delivering targeted radiation to prostate cancer. FDA-approved Pluvicto (177Lu-PSMA-617) + emerging actinium-PSMA-225 alpha-emitters. See now: /trials/prostate-cancer.
FRα Antibody-Drug Conjugates

Hub coming soon

Target: FRα (folate receptor alpha). ADCs for FRα-high cancers, primarily platinum-resistant ovarian. Mirvetuximab soravtansine (Elahere) + next-gen. See now: /trials/ovarian-cancer.
PARP Inhibitors

Hub coming soon

Target: PARP. Block DNA single-strand break repair in BRCA-mutated and HRD-positive cancers. Olaparib, niraparib, rucaparib, talazoparib, saruparib (PARP1-selective). Across ovarian, prostate, breast, pancreatic.
KRAS G12C Inhibitors

Hub coming soon

Target: KRAS G12C mutation + emerging pan-RAS inhibitors. Sotorasib (Lumakras), adagrasib (Krazati), divarasib, daraxonrasib (RMC-6236). See now: /drugs/daraxonrasib.
HER2 Antibody-Drug Conjugates

Hub coming soon

Target: HER2. ADCs for HER2+ and HER2-low cancers. Trastuzumab deruxtecan (Enhertu, T-DXd) + emerging HER2 ADCs across solid tumors. See now: /drugs/trastuzumab-deruxtecan.
Bispecific Checkpoint Inhibitors

Hub coming soon

Targets: PD-1, CTLA-4, VEGF, TIGIT, LAG-3. Cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), rilvegostomig (PD-1/TIGIT), and emerging combinations across NSCLC, HCC, cervical, gastric.

Don't know which mechanism class fits your situation?

Use ClinTrialFinder's AI-powered matching to search by disease, biomarker, or prior treatment history — no need to know the drug class up front.

Find Clinical Trials

Browsing by Disease or Drug Instead

If you already know the cancer type you're researching, start with the disease-specific trial pages. Browse trials by disease →

If you know the specific drug name your oncologist mentioned, the drug-anchored pages cover each drug in depth. Browse trials by drug →